: Vaccination delay for Indigenous children for the 3rd dose of pneumococcal conjugate vaccine, by state or territory, Australia, 2016 a 33 Figure 17 : Pneumococcal conjugate vaccine coverage at 12 months of age (three doses) by SA3, Australia and major capital cities, 2016 34 Figure 18 : Measles, mumps, rubella (MMR) coverage at 24 months of age (two doses) by SA3, Australia and major capital cities, 2016 Figure 19 : Diphtheria, tetanus, acellular pertussis (DTPa) coverage at 24 months of age (four doses) by SA3, Australia and major capital cities, 2016 (cohort of children born 1 October -31 December 2014 due 4 doses of DTPa) 37 Figure 20: Trends in the number of children aged 6 months to less than 10 years with at least one new vaccination exemption due to medical contraindication or natural immunity entered into the Australian Immunisation Register during each year, 2011-2016, by state/ territory, Australia a 39 Figure 21 : HPV vaccination coverage by dose number (Australia) for females by age group in mid-2016 a INTRODUCTION This is the 10th Annual Immunisation Coverage Report, with analysis now encompassing the years 2007-2016 with the publication of this report. [1] [2] [3] [4] [5] [6] [7] [8] [9] This report adds to and complements other reports providing data on immunisation coverage in Australia 10, 11 and highlights important trends, as well as policy and program changes in relation to them. It follows the format of previous reports, covering data for the calendar year 2016, and also includes new coverage data on adolescents and adolescent coverage data from previously published sources. Readers are referred to the first report for a more detailed explanation of the background, methods, and range of analyses presented. 1 This report uses the longstanding international practice of reporting at key milestone ages to measure coverage against national targets, and to track trends over time. Table 1 shows the Australian National Immunisation Program Schedule for 2016. 12 High levels of reporting to the Australian Immunisation Register (AIR), previously known as the Australian Childhood Immunisation Registration (ACIR), are maintained by a system of incentive payments for immunisation providers and carers. These have been discussed in detail elsewhere. 6, 13, 14 The Australian Childhood Immunisation Register (ACIR) was established on 1 January 1996 by incorporating demographic data from Medicare on all enrolled children under the age of 7 years. 15 On 30 September 2016, the ACIR expanded to become the Australian Immunisation Register (AIR) to collect data on vaccinations given from birth to death. 16 All people registered with Medicare are automatically added to the AIR. Participation in the AIR is 'opt-out' and so constitutes a nearly complete population register for Australian resident persons, as approximately 99% of persons are registered with Medicare by 12 months of age. 15 Persons not enrolled in Medicare can also be added to the AIR via a supplementary number. Since 2001, vaccinations given overseas may be recorded if a provider endorses their validity. Data are transferred to the AIR when a recognised immunisation provider supplies details of an eligible vaccination. This could occur either automatically from medical practice management software or through the internet using the AIR website or by submitting paper encounter or history forms. There is potential for under-reporting of some vaccinations to the AIR, especially 'non-universal' vaccines, given the lack of incentive payments for notification of these vaccines to the AIR. The existence of medical contraindications to immunisation is also recorded on the AIR. From 1 January 2016, conscientious objection is no longer a valid exemption to immunisation linked to family payments and therefore is no longer recorded on the AIR. 14 All vaccination records for a person remain on the register indefinitely.
Vaccinations recorded on the immunisation register must be rendered in accordance with the guidelines issued by the Australian Technical Advisory Group on Immunisation (ATAGI). 17 Notifications falling outside these guidelines, 
METHODS

Measuring immunisation coverage using the AIR
This report details immunisation coverage using AIR data up to 31st March 2017. The cohort method has been used for calculating coverage at the population level (national and state/ territory) 21 since the ACIR's inception. Cohort immunisation status was assessed at 12 months of age (for vaccines due at 6 months), 24 months of age (for vaccines due at 12 and 18 months), and 60 months of age (for vaccines due at 48 months). A minimum 3-month lag period was allowed for late notification of vaccinations to the AIR, but only vaccines given on or before a child's 1st, 2nd or 5th respective birthdays were included in coverage calculations. 21 If a child's records indicate receipt of the last dose of a vaccine that requires more than 1 dose to complete the series, it was assumed that earlier vaccines in the sequence have been given. This assumption has been shown to be valid in the past. 22, 23 Three-month-wide birth cohorts were used for time trend analyses, while both 3-month-wide and 12-month-wide cohorts were used for all other analyses in this report. The 12-month-wide cohorts used in this report were children born between 1 January 2015 and 31 December 2015 for the 12-month milestone; between 1 January 2014 and 31 December 2014 for the 24-month milestone; and between 1 January 2011 and 31 December 2011 for the 5-year (60-month) milestone.
The proportion of children designated as 'fully immunised' was calculated using the number of children completely immunised with the vaccines of interest by the designated age as the numerator, and the total number of Medicareregistered children in the age cohort as the denominator. 'Fully immunised' at 12 months of age was defined as a child having a record on the AIR of a 3rd dose of a diphtheria (D), tetanus (T) and pertussis-containing (P) vaccine, a 3rd dose of polio vaccine, a 2nd or 3rd dose of PRP-OMP containing Haemophilus influenzae type b (Hib) Coverage for seasonal influenza vaccine was calculated for Indigenous and non-Indigenous children aged 6 months to less than 5 years. The percentage of children who were recorded in the AIR as having received at least one dose of the seasonal influenza vaccine during 2016 was calculated.
Timeliness
'On-time' vaccination was defined as receipt of a scheduled vaccine dose within 30 days of the recommended age. For example, a child who received the first dose of DTPa (due by 60 days of age) when he or she was more than 90 days of age was classified as late for that dose. For descriptive purposes, we categorised the delay outcome measure for each dose as either 'delay of 1 -< 3 months', 'delay of 3 -< 7 months' or 'delay ≥ 7 months'. On-time vaccination was measured in 12-month-wide birth cohorts. Children included in the on-time vaccination analysis were assessed at 1-3 years after doses were due, to allow time for late vaccinations to be recorded. Therefore, these cohorts are not the same as those assessed for coverage milestones. The interval between doses was not evaluated. On-time vaccination for different vaccines and doses was also compared by plotting the cumulative percentage receiving each vaccine dose by age.
Remoteness status
The area of residence of children was defined as 'Major cities', 'Inner regional', 'Outer regional', 'Remote', and 'Very remote' using the Accessibility/Remoteness Index of Australia (ARIA++). 24 ARIA++ is a continuously varying index with values ranging from 0 (high accessibility) to 15 (high remoteness), and is based on road distance measurements from over 12,000 populated localities to the nearest service centres in five categories based on population size. For analysis in this report, we combined the two 'Regional' categories ('Inner regional' and 'Outer regional') into one category and the two 'Remote' categories ('Remote' and 'Very remote') into one category. ARIA Accessibility/ Remoteness categories were assigned for each child using their current recorded postcode of residence on the AIR.
Indigenous status
Aboriginal and Torres Strait Islander (Indigenous) status on the AIR is recorded as 'Indigenous', 'non-Indigenous' or 'unknown', as reported by the child's carer to Medicare or by the immunisation provider to the AIR. For this report we considered two categories of children: 'Indigenous' and 'non-Indigenous'; children with unknown Indigenous status were presumed to be 'non-Indigenous'. Coverage estimate time trends are presented from 2002 only, due to poor rates of reporting Indigenous status prior to then. 25
Small area analysis
Analysis for small areas was done by ABSdefined Statistical Area 3 (SA3), 26 chosen because each is small enough to show differences within jurisdictions but not too small to render maps unreadable. Maps were created using version 15 of the MapInfo mapping software 27 and the ABS Census Boundary Information.
As postcode is the only geographical indicator available from the AIR, the ABS Postal Area to SA3 Concordance 2011 was used to match AIR postcodes to SA3s. 28
Adolescent immunisation coverage as recorded on the AIR
Coverage estimates as recorded on the AIR for catch-up doses of the 2nd dose of MMR vaccine for adolescents were assessed at 10-19 years of age for all jurisdictions. We focused on the 2nd dose of MMR vaccine as it is not delivered via the school-based program. The 2nd dose was chosen rather than the 1st as some children might already have had the 1st dose previously i.e. partially vaccinated. We examined these catch-up doses in order to assess the potential impact of the 'No Jab No Pay' legislation, acknowledging that some of the children who received MMR2 in 2016 may have received it for unrelated reasons (eg prior to overseas travel or enrolment in a health-related training course).
Medical contraindication exemptions
The trends in the number of children aged 6 months to less than 10 years with at least one new vaccination exemption due to a medical contraindication or a natural immunity entered into the AIR during each year were calculated by state/territory for the years 2011-2016 using AIR data.
Human papillomavirus vaccine coverage
Data on HPV vaccination were provided by the National HPV Vaccination Program Register, which is operated by the Victorian Cytology Service. Coverage for a full course of HPV vaccine (defined as three doses of quadrivalent HPV vaccine at acceptable minimum dose intervals) was assessed for females and males aged 15 years (as recommended by the World Health Organization for the purposes of international comparison) in 2016. As HPV vaccination is delivered routinely in early high school usually at the age of 12-13 years, all children in each cohort have had the opportunity to complete the vaccination course by age 15. Numerator data comprise valid doses allocated to the child's state of residence and denominator data comprise Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) data, in contrast to Medicare enrolment data used as the denominator for AIR reporting and in the rest of this report. A previous study has found that ABS ERP denominator data produce coverage estimates comparable to Medicare enrolment data when applied to the early adolescent age group. 29 HPV coverage estimates were also provided separately for doses 1, 2 and 3 and by four age groups: 14-15 years; 16-17 years; 18-19 years; and 20-26 years of age. 
RESULTS
Coverage estimates 'Fully immunised'
Individual antigens within single or combination vaccines 12 months of age
Coverage at the 12-months age assessment milestone for antigens in the relevant combination vaccine (DTPa-hepB-polio-Hib) increased by around three percentage points between late 2014 and the end of 2016 (91.6% to 94.5%) ( Figure 2 ). Coverage for the third dose of PCV by 12 months of age has continued to rise steadily and reached 94.1% in late 2016, similar to the level of coverage for all other vaccines/antigens assessed at this age except for rotavirus vaccine. Rotavirus coverage is lower, due to strict upper age limits for administration, but has also increased since late 2014, reaching 87.5% in December 2016 ( Figure 2 ).
months of age
In 2016, coverage at the 24-months age assessment milestone increased for all vaccines/anti- gens except DTPa (Figure 3 ). Coverage estimates for the age assessment quarterly data points in December 2016 were 94% or greater for all vaccines/antigens except DTPa (91.8%) and MMRV (93.3%) ( Figure 3 ). The decrease in DTPa coverage from 96% is due to the coverage assessment algorithm being amended in late 2016 to include a 4th dose of DTPa instead of a 3rd dose (reflecting the change in the NIP). Following the decline in MMR coverage in the latter half of 2014, due to the 2nd dose of MMR-containing vaccine being assessed at 24 months of age for the first time instead of the 1st dose as previously, coverage steadily increased over 2015 and 2016.
For vaccines due at 48 months of age, trends in individual vaccine/antigen coverage were similar to that seen for 'fully immunised' coverage (Figure 4 ). Coverage for DTPa, polio and MMR all increased in 2016 to greater than 94% for the age assessment quarterly data points in December 2016 (Figure 4 ).
Indigenous coverage estimates 'Fully immunised'
The proportion of Indigenous children 'fully immunised' by 24 months of age was consistently higher than at either the 12-or 60-month milestones until 2012, when coverage at 60 months rose to comparable levels (Figures 5, 6 and 7). 'Fully immunised' coverage at 12 and 60 months in Indigenous children has steadily increased since 2012, reaching 92.1% and 95.4%, respectively, by the end of 2016. During the latter half of 2014, the proportion of Indigenous children 'fully immunised' by 24 months of age decreased by 8.5 percentage points, coinciding with the changes to the 'fully immunised' coverage algorithm ( Figure 6 ). 'Fully immunised' coverage at 24 months in Indigenous children then increased to 90.4% in mid-2016 but fell to 87.2% at the end of 2016, when the coverage assessment algorithm was amended in the last quarter of 2016 to include a 4th dose of DTPa instead of a 3rd dose. 
Hepatitis A vaccine for Indigenous children
For the four jurisdictions in which hepatitis A vaccine is funded for Indigenous children (Northern Territory, Queensland, South Australia and Western Australia), combined coverage of the second dose of hepatitis A vaccine by 30 months of age was steady at close to 60% from 2010 to 2014 but then increased, reaching 72.4% by the end of 2016 (Figure 8 ). Coverage has consistently been highest in the Northern Territory (86.2% at the end of 2016). By late 2016, coverage was greater than 64% in all jurisdictions (Figure 8 ).
Pneumococcal vaccine for Indigenous children
For the four jurisdictions in which an 18-month booster dose of pneumococcal conjugate vaccine is funded for Indigenous children (Northern Territory, Queensland, South Australia and Western Australia) combined coverage increased following the 13vPCV catch-up campaign in 2012, fell in 2013, but then increased again reaching 74.3% by the end of 2016 ( Figure  9 ). Coverage has consistently been highest in the Northern Territory (86.5% at the end of 2016). By late 2016, coverage was greater than 68% in all jurisdictions (Figure 9 ).
Recorded influenza vaccine coverage for Indigenous children aged 6 months to <5 years
Recorded influenza vaccine coverage in Indigenous children aged 6 months to <5 years was generally low across Australia in 2016, with overall national coverage of 11.6%. There was substantial variation in recorded coverage between the jurisdictions (Figure 10) . Apart from the Northern Territory (55.5%), coverage was only above 10% in Queensland and Western Australia (12.6% and 12.2%, respectively). For non-Indigenous children aged 6 months to <5 years, coverage of the seasonal influenza vaccine in 2016 was recorded as 2.7% in Australia, and coverage in all jurisdictions was below 10% (Figure 10 ).
There was also substantial variation in 2016 in influenza vaccine coverage by age within the 6 months to <5 years age group of Indigenous children (Figure 11 ). Coverage at a national level was highest in the youngest age group (6 months to <1 year; 15.1%) and lowest in the oldest age group (4-<5 years; 8.0%). Lower coverage in the 2-<3 year age group, compared to the 3-<4 year age group, may reflect the lack of any scheduled vaccination milestones in the former. Figure 12 shows the time trend of seasonal influenza vaccine coverage recorded on the AIR between 2007 and 2016 for Indigenous children aged 6 months to <5 years, by jurisdiction. Coverage in Western Australia peaked at 28% in 2009 following the introduction in 2008 of a statefunded universal immunisation program for all children aged 6 months to <5 years. However, it was substantially lower in subsequent years due to suspension of the program in 2010 following increased febrile reactions, later shown to be related to a single brand of influenza vaccine. Following the commencement of the nationally funded program for Indigenous children aged 6 months to <5 years in 2015, seasonal influenza vaccine coverage rose to 12.1% nationally in 2015, with a slight decrease to 11.6% in 2016 ( Figure 12 ). Similar upward trends in coverage over time were seen for all jurisdictions, but coverage remains highest in the Northern Territory, Queensland and Western Australia. Compared with 2014, influenza vaccine coverage in 2016 has increased almost 12-fold in the Northern Territory and 5-fold in Queensland. Figure 13 shows the percentage of influenza vaccines given to Indigenous children aged 6 months -< 5 years at/not at the same time as other scheduled vaccinations. More than half received their first reported dose of influenza vaccine on a separate day to other scheduled vaccines. This proportion increased with subsequent doses. This likely reflects subsequent doses being predominantly given at older ages where there are less scheduled vaccination points. Of those receiving an influenza vaccine on the same day as other scheduled vaccines, the largest proportion was administered with vaccines due at the 4-year-old milestone. This may reflect less frequent visits of older children to providers, and hence less opportunities for vaccination at other times.
Timeliness of immunisation
Timeliness for the 2nd and 3rd doses of DTPa by Indigenous status is shown in Figure 14 .
The differential between Indigenous and non-Indigenous children was 13.6% and 17.5% lower, respectively. The differential for the 3rd dose of DTPa was 0.9 of a percentage point lower compared to 2015.
Similar patterns were found for timeliness of the 1st dose of MMR vaccine by 13 months of age and the 2nd dose of MMR vaccine by 19 months of age (Figure 15 ), although the differentials were smaller (11.5% and 15.7% for the 1st and 2nd dose, respectively). The differential for the 1st dose of MMR was 0.2 of a percentage point lower compared to 2015, while the differential for the 2nd dose of MMR was unchanged.
Delayed receipt of the 3rd dose of DTPa, the 1st dose of MMR, and the 2nd dose of MMR vaccines by Indigenous and remoteness status in 2016 is shown in Table 3 . For both Indigenous and non-Indigenous children, the majority of delay occurred 1 -<3 months after the schedule point for all three vaccine doses, and across all remoteness categories. The proportion of Indigenous children living in major cities with a delay of 1 -<3 months for the 3rd dose of DTPa and the 2nd dose of MMR was lower compared to Indigenous children living in remote and very remote areas (18.6% vs. 23.3%, and 23.8% vs. 26.9%, respectively), but the proportion with very late vaccination (≥7 months after the schedule point) was higher (7.1% vs. 5.9% and 7.3% vs. 5.8%, respectively) ( Table 3) .
Vaccination delay for Indigenous children by jurisdiction in 2016 was measured for the 3rd dose of PCV (Figure 16) , with the highest proportions experiencing delay of 1 -<3 months found in Western Australia (23.8%) and the Northern Territory (23.2%). The proportion with delay of 3 -<7 months ranged from 3.1% in the Australian Capital Territory to 14.0% in Western Australia, and the proportion with delay of ≥7 months ranged from 2.4% in Tasmania to 7.9% in Western Australia.
Small area coverage analysis
Immunisation coverage in Australia in 2016 varied substantially within jurisdictions and major capital cities, with some areas substantially below the national averages, especially for vaccines due at an older age (Figures 17-19) . For the fourth dose of DTPa by 24 months of age, there were ten SA3s with coverage below 85% ( Figure 19 ). Figure 20 shows the trends in the number of children aged 6 months to less than 10 years with at least one new vaccination exemption due to a medical contraindication or a natural immunity entered into the AIR during each year, by state/ territory, from 2011 to 2016. From 2011 to 2015 there was a clear trend of increasing numbers of exemptions. Exemptions more than doubled in 2015 compared with 2014 (635 to 1,401), but 
Adolescent immunisation catch-up coverage for 2nd dose of MMR
Medical contraindication exemptions
Provider type
In 2016, the large majority of vaccinations in Australia were administered in general practice settings (78.8%, up from 72% in 2012; data not shown). Councils delivered 8.9%, and Community and Aboriginal Health Services delivered 7.5%.
Mechanisms of reporting to the AIR
The proportion of vaccinations on the AIR lodged by electronic/online mechanisms in 2016 for Australia was 96.1%, up from 85.2% in 2012 (data not shown).
Human papillomavirus vaccine coverage
Vaccination coverage, as notified to the National HPV Vaccination Program Register, for dose 3 of the HPV vaccine for females and males aged 15 years in 2016, is shown in Coverage in all age groups remains higher for earlier doses. In females, coverage was highest (87%) for the 1st dose in the 14-to 15-year-old age group (Figure 21 ). Coverage was higher in the younger age groups than the older age groups, with only 59% of females aged 20-26 years fully vaccinated compared to 79% of females aged 14-15 years. As with data for females, male coverage in all age groups was higher for earlier doses (Figure 22 ). In males, coverage for the 1st dose in the 14-to 15-year-old age group was up three percentage points from 2015 at 83%, and up twenty percentage points from 2015 at 74% in the 16-to 17-year-old age group. Coverage for the 3rd dose was 63% in males aged 16-17 years.
HPV coverage estimates by Indigenous status are not currently available due to limitations in Indigenous status reporting to the HPV Register.
DISCUSSION
'Fully immunised' coverage at the 12-month age assessment milestone, after a decade of being largely stable at around 90%, increased in 2015 30, 31 'Fully immunised' coverage at 12 and 60 months of age in Indigenous children has steadily increased since 2012, reaching 92.1% and 95.4%, respectively, for the age assessment quarterly data points in December 2016. The gap in 'fully immunised' coverage between Indigenous and non-Indigenous children at 12 months of age has closed considerably from 6.7 percentage points in 2013 to 1.7 percentage points for the age assessment quarterly data point in December 2016. Coverage for Indigenous children at 60 months of age has been higher than in non-Indigenous children since 2012. In contrast, at 24 months of age, 'fully immunised' coverage, while similar in Indigenous and non-Indigenous children from 2011 to 2013, was more disparate with a gap of 2.6% at the end of 2016. This is likely due to the incorporation of additional vaccine doses in the 24-month coverage algorithm in 2014 and 2016, with a differential impact on assessment of coverage in Indigenous children related to timeliness issues.
Recorded coverage in the influenza immunisation program for Indigenous children aged 6 months to <5 years (which commenced in 2015) was low in 2016, with overall national coverage of 11.6%, and only the Northern Territory (55.5%) achieving coverage above 15%. However, upward trends in coverage of Indigenous children over time were seen for all jurisdictions, with coverage highest in the Northern Territory, Queensland and Western Australia. Compared with 2014, influenza vaccine coverage in 2016 has increased almost 12-fold in the Northern Territory and 5-fold in Queensland. Unlike other vaccines on the NIP, influenza vaccine notifications do not attract notification payments for immunisation providers. As such, influenza vaccine coverage data should be regarded as a minimum estimate due to the potential for under-reporting. Other factors contributing to the low coverage may include parental and provider attitudes and concerns, along with other issues such as the seasonal nature of the program, the two doses required in the first year a child under 9 years of age receives influenza vaccine, and the 'gap' in NIP funding for 5-to 14-year-old Indigenous children.
Coverage for established programs of vaccines targeted specifically at Indigenous children (i.e. hepatitis A and a booster dose of pneumococcal conjugate vaccine) have increased in recent years but still remain suboptimal. Both these vaccines are included on the NIP for Indigenous children in the Northern Territory, Queensland, South Australia, and Western Australia. From 2007 to the end of 2016, coverage for the 2nd dose of hepatitis A vaccine increased considerably from around 30% to 72.4% for these four jurisdictions combined, and was higher than 64% in each. The national hepatitis A immunisation program has been shown to have had a significant impact in the targeted population with relatively modest vaccine coverage, with evidence suggestive of substantial herd protection effects. 32 Coverage of the pneumococcal booster dose increased to 74.3% for the four jurisdictions combined, and was greater than 68% in each. The extent of under-reporting to the AIR for hepatitis A vaccine and the pneumococcal booster is unknown, but may be more than for 'universal' vaccines, given the lack of incentive payments for notification to the AIR. However, lower coverage for vaccines targeted specifically at Indigenous people has been a relatively consistent finding for both children 33 and adults. 34 Both a lack of provider knowledge about the recommendations for high-risk groups, and suboptimal identification of Indigenous children by immunisation providers, are likely to be important contributing factors.
Although most children eventually complete the scheduled vaccination series, many still do not do so in a timely manner. On-time vaccination (within 30 days of the recommended age) for the 3rd dose of DTPa, and the 1st dose of MMR, in 2016 increased for both Indigenous and non-Indigenous children, compared to 2015. However, timeliness remains an ongoing problem for Indigenous children in Australia. As younger children are often more vulnerable to severe disease, immunisation at the earliest appropriate age should be a public health goal for countries such as Australia where high levels of vaccine coverage at milestone ages have been achieved.
Of adolescents aged 10-19 years recorded as not having received their second dose of MMR vaccine by 31 December 2015, 43,103 (10.5%) received it in 2016. Many of these doses are likely to have been administered as a result of the introduction on 1 January 2016 of the Australian Government's 'No Jab No Pay' policy, which included special provisions for catch-up doses. This policy introduced annual immunisation requirements for eligibility for federal government family assistance payments through to 19 years of age, and removed nonmedical exemptions. This additional MMR vaccination of adolescents is of importance considering that, following a 2nd MMR vaccine dose, approximately 99% of subjects overall will be immune to measles.
In 2016, parental vaccination objection could not be estimated as data is no longer collected by the AIR. The number of children aged 6 months to 10 years of age with new medical exemptions, which had increased sharply in 2015, decreased in all jurisdictions in 2016. This decrease is likely due to the stricter eligibility criteria introduced in 2016. 35 Exploration of children with at least one medical exemption for a vaccine by geographical area, looking for any 'hotspots', will be undertaken as part of a separate report.
Coverage for the HPV vaccine, as derived from the National HPV Vaccination Program Register, continues to increase reflecting a successful school-based program. 36, 37 The rapid and substantial decrease in HPV prevalence in young women, 38 and the comparable decreases in genital warts 39 and cervical abnormalities, 40, 41 reflect this high coverage as well as the substantial initial catch-up component, which played a major role in bringing forward the benefits of vaccination in the population. 42 Coverage continues to rise in males as the program has become a routine gender-neutral program. With recent modelling of HPV vaccination programs suggesting that sustained vaccination coverage of over 80% in females and males will be sufficient for elimination of targeted HPV types, Australia looks well placed to realise this into the future. 43 In conclusion, data provided in this report reflect continuing successful delivery of the NIP in Australia, while identifying some areas for improvement, particularly in timeliness of vaccination for Indigenous children and in coverage of vaccines specifically targeted to Indigenous children.
